Inhibition of T-cell activition with HLA-DR1/DR4 restricted non-T-cell stimulating peptides

Human Immunology

Volumn 64, Issue 9, 2003, Pages 857-865

  Zhou, Qiang ^a   Cheng, Yongjing ^a   Lü, Houshan ^a   Zhou, Weihong ^b   Li, Zhanguo ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b TSINGHUA UNIVERSITY   (China)

Author keywords

Activation; Altered peptides; Collagen II; HLA DR; T cell

Indexed keywords

COLLAGEN TYPE 2; COLLAGEN TYPE 2 DERIVED PEPTIDE; HLA DR1 ANTIGEN; HLA DR4 ANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONFOCAL MICROSCOPY; FLOW CYTOMETRY; HYDROGEN BOND; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0041833385     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(03)00143-5     Document Type: Article

References (37)

1. Nepom GT, Byers P, Seyfried C, Healey LA, Wilskie KR, Stage D, Nepom BS: HLA genes associated with rheumatoid arthritis. Identification of susceptibility alleles using specific oligonucleotide probes. Arthritis Rheum 32:15, 1989.
2. Ohta N, Nishimura YK, Tanimoto K, Horiuchi Y, Abe C, Shiokawa Y, Abe T, Katagiri M, Yoshiki T, Sasazuki T, Ohta B, Nishimura YK, Tanimoto K: Association between HLA and Japanese patients with rheumatoid arthritis. Hum Immunol 5:23, 1982.
3. Deighton CM, Kelly PJ, Walker DJ: Linkage of rheumatoid arthritis with HLA. Ann Rheum Dis 52:638, 1993.
4. Sanchez B, Moreno I, Magarino R, Garzon M, Gonzalez MF, Garcia A, Nunez-Roldan A, Sanchez B, Moreno I, Magarino R: HLA-DRw10 confers the highest susceptibility to rheumatoid arthritis in Spanish population. Tissue Antigens 36:174, 1990.
5. Gao XJ, Brautbar C, Gazit E, Segal R, Naparstek Y, Livneh A, Stastny P: A variant of HLA-DR4 determine susceptibility to rheumatoid arthritis in a subset of Israeli Jews. Arthritis Rheum 34:547, 1991.
6. Gregersen PK, Silver J, Winchester RJ: The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30:1205, 1987.
7. Willkens RF, Nepom GT, Maks C, Nettle JW, Nepom BS: Association of HLA-Dw16 with rheumatoid arthritis in Yakima Indian: further evidence for the "share epitope" hypothsis. Arthritis Rheum 34:43, 1991.
8. Gregersen PK, Shen M, Song QL, Merryman P, Degar S, Seki T, Maccari J, Goldgerg D, Murphy H, Schwenzer J, Wang CY, Winchester RJ, Nepom GT, Silver J: Molecular diversity of HLA-DR4 haplotypes. Proc Natl Acad Sci USA 83:2642, 1986.
9. Hammer J, Gallazzi F, Bono E, Karr RW, Guenot J, Valsasnini P, Nagy ZA, Sinigaglia F: Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J Exp Med 181:1847, 1995.
10. Rammensee HG, Friede T, Stevanoviic S: MHC ligands and peptide motifs: first listing. Immunogenetics 41:178, 1995.
11. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, Wiley DC: Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368:215, 1994.
12. Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC: X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 7:473, 1997.
13. Ghosh P, Amaya M, Mellins E, Wiley DC: The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378:457, 1995.
14. Fremont DH, Hendrickson WA, Marrack P, Kappler J: Structures of an MHC class II molecule with covalently bound single peptides. Science 272:1001, 1996.
15. Jardetzky TS, Brown JH, Gorga JC, Stern LJ, Urban RG, Chi YI, Stauffacher C, Strominger JL, Wiley DC: Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 368:711, 1994.
16. Fugger L, Michie SA, Rulifson I, Lock CB, McDevitt GS: Expression of HLA-DR4 and human CD4 transgenes in mice determines the variable region beta-chain T-cell repertoire and mediates an HLA-DR-restricted immune response. Proc Natl Acad Sci USA 91:6151, 1994.
17. Kim HY, Kim WU, Cho ML, Lee SK, Youn J, Kim SI, Yoo WH, Park JH, Min JK, Lee SH, Park SH, Cho CS: Enhanced T cell proliferative response to type II collagen and synthetic peptide CII (255-274) in patients with rheumatoid arthritis. Arthritis Rheum 42:2085, 1999.
18. Diab BY, Lambert NC, L'Faqihi FE, Loubet-Lescoulie P, de Preval C, Coppin H: Human collagen II peptide 256-271 preferentially binds to HLA-DR molecules associated with susceptibility to rheumatoid arthritis. Immunogenetics 49:36, 1999.
19. Myers LK, Tang B, Rosloniec EF, Stuart JM, Chiang TM, Kang AH: Characterization of a peptide analog of a determinant of type II collagen that suppresses collagen-induced arthritis. J Immunol 161:3589, 1998.
20. Rosloniec EF, Whittington KB, Brand DD, Myers LK, Stuart JM: Identification of MHC class II and TCR binding residues in the type II collagen immunodominant determinant mediating collagen-induced arthritis. Cell Immunol 172:21, 1996.
21. Andersson EC, Hansen BE, Jacobsen H, Madsen LS, Andersen CB, Engberg J, Rothbard JB, McDevitt GS, Malmstrom V, Holmdahl R, Svejgaard A, Fugger L: Definition of MHC and T cell receptor contacts in the HLADR4-restricted immunodominant epitope in type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 transgenic mice. Proc Natl Acad Sci USA 95:7574, 1998.
22. Rosloniec EF, Brand DD, Myers LK, Whittington KB, Gumanovskaya M, Zaller DM, Woods A, Altmann DM, Stuart JM, Kang AH: An HLA-DR1 transgene confer susceptibility to collagen-induced arthritis elicited with human type II collagen. J Exp Med 185:113, 1997.
23. Fugger L, Rothbard JB, Sonderstrup-McDveitt G: Specificity of an HLA-DRB1*0401-restricted T cell response to type II collagen. Eur J Immunol 26:928, 1996.
24. Rosloniec EF, Whittington KB, Zaller DM, Kang AH: HLA-DR1 (DRB1*0101) and DR4 (DRB1*0401) use the same anchor residues for binding an immunodominant peptide derived from human type II collagen. J Immunol 168:253, 2002.
25. Zhou Q, Cheng YJ, Zhang XW, Lü HS, Li ZG: Inhibition of collagen-induced arthritis by HLA-DRβ1 sepicific non-T cell binding peptides. Chin J Rheumatol 6:397, 2002.
26. Morris GM, Goodsell DS, Huey R, Hart WE, Halliday S, Belew R, Olson AJ: AutoDock. Volume 3.0. La Jolla, CA: The Scripps Research Institute, 1999.
27. Goodford PJ: A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 28:849, 1985.
28. Morris GM, Goodsel DS, Hallida RS, Huey R, Hart WE, Belwe RK, Olson AJ: Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comp Chem 19:1639, 1998.
29. Sharp K, Fine R, Honig B: Computer simulations of the diffusion of a substrate to an active site of an enzyme. Science 236:1460, 1987.
30. Fridkis-Hareli M, Rosloniec EF, Fugger L, Strominger JL: Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones. Proc Natl Acad Sci USA 95:12528, 1998.
31. Fridkis-Hareli M, Rosloniec EF, Fugger L, Strominger JL: Synthetic peptides that inhibit binding of the collagen type II 261-273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses. Hum Immunol 61:640, 2000.
32. Aharoni R, Teitelbaum D, Arnon R: Suppressor hybridomas and interleukin-2-dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis. Eur J Immunol 23:17, 1993.
33. Teitelbaum D, Milo R, Arnon R, Sela M: Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci USA 89:137, 1992.
34. Teitelbaum D, Fridkis-Hareli M, Arnon R, Sela M: Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J Neuroimmunol 64:209, 1996.
35. Fridkis-Hareli M, Teitelbaum D, Gurevich E, Pecht I, Brautbar C, Kwon OJ, Brenner T, Arnon R, Sela M: Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells - specificity and promiscuity. Proc Natl Acad Sci USA 91:4872, 1994.
36. Fridkis-Hareli M, Teitelbaum D, Arnon R, Sela M: Synthetic copolymer 1 and myelin basic protein do not require processing prior to binding to class II major histocompatibility complex molecules on living antigen-presenting cells. Cell Immunol 163:229, 1995.
37. Fridkis-Hareli M, Strominger JL: Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J Immunol 160:4386, 1998.